Lina Zielke
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Lina Zielke has a total of 11 co-authors. Here are the top co-authors by number of shared publications:
- Andrea Sinz
Department of Pharmaceutical Chemistry and Bioanalytics, Martin Luther University Halle-Wittenberg, Halle (Saale), Germany
1 shared publication - Anne Sophie Czerniak
Institute of Biochemistry Faculty of Life Sciences Leipzig University Brüderstr. 34 04103 Leipzig Germany
1 shared publication - Annette Gabriele Beck‐Sickinger
Institute of Biochemistry Leipzig University Leipzig Germany
1 shared publication Christian H. Ihling
Department of Pharmaceutical Chemistry and Bioanalytics, Martin-Luther-University Halle-Wittenberg, Halle, Germany
1 shared publicationSigne Mathiasen
Department of Biomedical Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Copenhagen, Denmark
1 shared publication- Sylvia Els-Heindl
Universität Leipzig
1 shared publication
Latest Publications
- Open Access
- 1 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Self-cleavage of the GAIN domain of adhesion G protein-coupled receptors requires multiple domain-extrinsic factors
The autoproteolysis-inducing (GAIN) domain of class B2/adhesion G protein-coupled receptors (aGPCRs) is structurally conserved, and its self-cleavage is central to receptor mechanotransduction and signaling. Yet, the influence of factors beyond the protein fold on GAIN domain autoproteolysis remains unclear. Using ADGRE2/EMR2, a self-cleaved aGPCR, we investigated contributions of the seven-transmembrane (7TM) region to GAIN domain autoproteolysis during receptor maturation and trafficking. Retention Upon Selective Hook (RUSH) assays showed that self-cleavage acts as a checkpoint before endoplasmic reticulum (ER) exit, but not during plasma membrane transport. Stepwise truncations of the 7TM domain revealed that cleavage can occur before or at synthesis of the first transmembrane helix, and is enhanced with formation of the full 7TM domain. Analyses of six additional cleavage-competent aGPCRs demonstrated that ER membrane tethering facilitates GAIN domain processing, supported by proteomic evidence linking cleavage to proximity with the N-glycosylation pathway. These results highlight the interplay between GAIN and 7TM domains, offering mechanistic insights and guiding pharmacological strategies to modulate aGPCR activation and signaling.
- 1 October 2025
- Published by Springer Nature in Nature Communications
- Vol. 16 (1) , 1-16
Open AccessSelf-cleavage of the GAIN domain of adhesion G protein-coupled receptors requires multiple domain-extrinsic factors
The autoproteolysis-inducing (GAIN) domain of class B2/adhesion G protein-coupled receptors (aGPCRs) is structurally conserved, and its self-cleavage is central to receptor mechanotransduction and signaling. Yet, the influence of factors beyond the protein fold on GAIN domain autoproteolysis remains unclear. Using ADGRE2/EMR2, a self-cleaved aGPCR, we investigated contributions of the seven-transmembrane (7TM) region to GAIN domain autoproteolysis during receptor maturation and trafficking. Retention Upon Selective Hook (RUSH) assays showed that self-cleavage acts as a checkpoint before endoplasmic reticulum (ER) exit, but not during plasma membrane transport. Stepwise truncations of the 7TM domain revealed that cleavage can occur before or at synthesis of the first transmembrane helix, and is enhanced with formation of the full 7TM domain. Analyses of six additional cleavage-competent aGPCRs demonstrated that ER membrane tethering facilitates GAIN domain processing, supported by proteomic evidence linking cleavage to proximity with the N-glycosylation pathway. These results highlight the interplay between GAIN and 7TM domains, offering mechanistic insights and guiding pharmacological strategies to modulate aGPCR activation and signaling.
- Open Access
Cyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment
Chemerin is a small chemotactic protein and a modulator of the innate immune system. Its activity is mainly mediated by the chemokine-like receptor 1 (CMKLR1), a receptor expressed by natural killer cells, dendritic cells, and macrophages. Downregulation of chemerin is part of the immune evasion strategy exploited by several cancer types, including melanoma, breast cancer, and hepatocellular carcinoma. Administration of chemerin can potentially counteract these effects, but synthetically accessible, metabolically stable analogs are required. Other tumors display overexpression of CMKLR1, offering a potential entry point for targeted delivery of chemotherapeutics. Here, we present cyclic derivatives of the chemerin C-terminus (chemerin-9), the minimal activation sequence of chemerin. Chemerin-9 derivatives that were cyclized through positions four and nine retained activity while displaying full stability in blood plasma for more than 24 h. Therefore, these peptides could be used as a drug shuttle system to target cancer cells as demonstrated here by methotrexate conjugates.
Open AccessCyclic Derivatives of the Chemerin C-Terminus as Metabolically Stable Agonists at the Chemokine-like Receptor 1 for Cancer Treatment
Chemerin is a small chemotactic protein and a modulator of the innate immune system. Its activity is mainly mediated by the chemokine-like receptor 1 (CMKLR1), a receptor expressed by natural killer cells, dendritic cells, and macrophages. Downregulation of chemerin is part of the immune evasion strategy exploited by several cancer types, including melanoma, breast cancer, and hepatocellular carcinoma. Administration of chemerin can potentially counteract these effects, but synthetically accessible, metabolically stable analogs are required. Other tumors display overexpression of CMKLR1, offering a potential entry point for targeted delivery of chemotherapeutics. Here, we present cyclic derivatives of the chemerin C-terminus (chemerin-9), the minimal activation sequence of chemerin. Chemerin-9 derivatives that were cyclized through positions four and nine retained activity while displaying full stability in blood plasma for more than 24 h. Therefore, these peptides could be used as a drug shuttle system to target cancer cells as demonstrated here by methotrexate conjugates.